Basket cover image
13 handpicked stocks

Stagflation Standouts

This collection features stocks and assets carefully selected by professional analysts to potentially outperform during stagflation periods. These defensive investments have already shown strength while the broader market struggles, making them worth consideration for economic uncertainty ahead.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+3

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at mai 19

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

GLD

Gold Shares SPDR

GLD

Current price

$305.27

COST

Costco Wholesale

COST

Current price

$980.85

WMT

Walmart Inc.

WMT

Current price

$101.29

About This Group of Stocks

1

Our Expert Thinking

Stagflation combines slow economic growth with persistent high inflation, creating challenges for many investments. We've identified assets from Bank of America's Stagflation basket that historically perform well in these conditions, focusing on essential industries that maintain demand regardless of economic conditions.

2

What You Need to Know

These defensive assets have already outperformed the broader market in 2025, rising over 3% while the S&P 500 fell more than 4%. This collection includes gold and companies in utilities, real estate, healthcare, and consumer staples – sectors providing goods and services people need regardless of economic conditions.

3

Why These Stocks

Each asset was selected based on its historical performance during stagflationary periods and its defensive characteristics. These are primarily S&P 500 companies representing industries that provide essential products and services, along with gold, which often serves as a hedge against inflation and economic uncertainty.

Group Performance Snapshot

13 of 13

Stocks Rated Buy by Analysts

13 of 13 assets in this group are rated Buy by professional analysts.

0.7%

Group Growth

This group averaged a 0.7% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

⚖️

Bucking the Downward Trend

While the S&P 500 has dropped over 4% this year, these stagflation-resistant picks have gained more than 3%. This performance gap could widen if economic conditions continue to deteriorate while inflation remains stubborn.

🛡️

Recession-Resistant Essentials

These companies provide products and services people need regardless of economic conditions. From utilities and healthcare to groceries and gold, they represent industries that maintain demand even when consumers tighten their belts.

🔮

Fed Forecasts Signal Opportunity

The Federal Reserve just lowered its 2025 growth forecast while raising inflation expectations, creating precisely the conditions these assets are selected to thrive in. This early positioning could benefit investors before stagflation concerns become widespread.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.